PILZ GEORG
Department of Neurology
Publications
66 Publications
2023
Journal Articles
Immunomodulatory Aspects of Therapeutic Plasma Exchange in Neurological Disorders-A Pilot Study.
Foettinger, F; Pilz, G; Wipfler, P; Harrer, A; Kern, JM; Trinka, E; Moser, T;
Int J Mol Sci. 2023; 24(7):
Full papers/articles (Journal)
2022
Journal Articles
The CXCL13/CXCR5 Immune Axis in Health and Disease-Implications for Intrathecal B Cell Activities in Neuroinflammation
Harrer, C; Otto, F; Radlberger, RF; Moser, T; Pilz, G; Wipfler, P; Harrer, A
CELLS-BASEL. 2022; 11(17): 2649
Reviews
Long-term immunological consequences of anti-CD20 therapies on humoral responses to COVID-19 vaccines in multiple sclerosis: an observational study.
Moser, T; OSullivan, C; Otto, F; Hitzl, W; Pilz, G; Schwenker, K; Mrazek, C; Haschke-Becher, E; Trinka, E; Wipfler, P; Harrer, A;
Ther Adv Neurol Disord. 2022; 15: 17562864221092092
Full papers/articles (Journal)
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser, T; Otto, F; OSullivan, C; Hitzl, W; Pilz, G; Harrer, A; Trinka, E; Wipfler, P;
Mult Scler Relat Disord. 2022; 59: 103560
Full papers/articles (Journal)
Tick-Borne Encephalitis Virus RNA Found in Frozen Goatxxxs Milk in a Family Outbreak
Mylonaki, E; Seiberl, M; Jones, N; Bernhard, H; Otto, F; Pilz, G; Trinka, E; Wipfler, P
INT J MOL SCI. 2022; 23(19): 11632
Case Reports
Misinterpretation of glioblastoma as ADEM: potentially harmful consequences of over-diagnosis of COVID-19 vaccine-associated adverse events.
O Sullivan, C; Zach, F; Moser, T; Pilz, G; Harrer, A; Trinka, E; Enzinger, C; Pfaff, JAR; Wipfler, P;
J Neurol. 2022; 269(2):616-618
Letters
Conference papers, proceedings, abstracts
Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications
Moser, T; Otto, F; Pilz, G; Wipfler, P
EUR J NEUROL. 2022; 29: 395-395.
Abstracts (Journal)
2021
Journal Articles
The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF
Harrer, C; Otto, F; Pilz, G; Haschke-Becher, E; Trinka, E; Hitzl, W; Wipfler, P; Harrer, A
FLUIDS BARRIERS CNS. 2021; 18(1): 40
Full papers/articles (Journal)
Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy.
Moser, T; OSullivan, C; Puttinger, C; Feige, J; Pilz, G; Haschke-Becher, E; Cadamuro, J; Oberkofler, H; Hitzl, W; Harrer, A; Kraus, J; Trinka, E; Wipfler, P;
Biomedicines. 2021; 9(11):
Full papers/articles (Journal)
Tetravalent Influenza Vaccine Is Not Associated With Neuroaxonal Damage in Multiple Sclerosis Patients.
Moser, T; Seiberl, M; Feige, J; Bieler, L; Radlberger, RF; OSullivan, C; Pilz, G; Harrer, A; Schwenker, K; Haschke-Becher, E; Machegger, L; Grimm, J; Redlberger-Fritz, M; Buchmann, A; Khalil, M; Kvas, E; Trinka, E; Wipfler, P;
Front Immunol. 2021; 12:718895
Full papers/articles (Journal)
Role and Relevance of Cerebrospinal Fluid Cells in Diagnostics and Research: State-of-the-Art and Underutilized Opportunities.
Otto, F; Harrer, C; Pilz, G; Wipfler, P; Harrer, A;
Diagnostics (Basel). 2021; 12(1):
Reviews
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.
Radlberger, RF; Sakic, I; Moser, T; Pilz, G; Harrer, A; Wipfler, P;
Mult Scler Relat Disord. 2021; 48:102727
Full papers/articles (Journal)
2020
Journal Articles
Neurological complications associated with influenza in season 2017/18 in Austria- a retrospective single center study.
Mylonaki, E; Harrer, A; Pilz, G; Stalzer, P; Otto, F; Trinka, E; Wipfler, P;
J Clin Virol. 2020; 127: 104340
Full papers/articles (Journal)
Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction.
Pilz, G; Sakic, I; Wipfler, P; Kraus, J; Haschke-Becher, E; Hitzl, W; Trinka, E; Harrer, A;
Fluids Barriers CNS. 2020; 17(1): 7
Full papers/articles (Journal)
Beyond LNB: Real life data on occurrence and extent of CSF CXCL13 in neuroinflammatory diseases.
Pilz, G; Steger, R; Wipfler, P; Otto, F; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A;
J Neuroimmunol. 2020; 338:577087
Full papers/articles (Journal)
2019
Journal Articles
Epidemiology of status epilepticus in adults: A population-based study on incidence, causes, and outcomes.
Leitinger, M; Trinka, E; Giovannini, G; Zimmermann, G; Florea, C; Rohracher, A; Kalss, G; Neuray, C; Kreidenhuber, R; Höfler, J; Kuchukhidze, G; Granbichler, C; Dobesberger, J; Novak, HF; Pilz, G; Meletti, S; Siebert, U;
Epilepsia. 2019; 60(1): 53-62.
Full papers/articles (Journal)
Cerebrospinal fluid CXLC13 indicates disease course in neuroinfection: an observational study.
Pilz, G; Wipfler, P; Otto, F; Hitzl, W; Afazel, S; Haschke-Becher, E; Trinka, E; Harrer, A;
J Neuroinflammation. 2019; 16(1): 13
Full papers/articles (Journal)
2018
Journal Articles
Intravenous brivaracetam in status epilepticus: A retrospective single-center study.
Kalss, G; Rohracher, A; Leitinger, M; Pilz, G; Novak, HF; Neuray, C; Kreidenhuber, R; Höfler, J; Kuchukhidze, G; Trinka, E;
Epilepsia. 2018; 59 Suppl 2: 228-233.
Reviews
Factor VII deficiency in major artery occlusion stroke.
Pikija, S; Gampenrieder, SP; Millesi, K; Pilz, G; Weis, S; Mutzenbach, JS
AM J HEMATOL. 2018; 93(6): 843-845.
Case Reports
Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: A single-center audit of 30 patients.
Rohracher, A; Kalss, G; Neuray, C; Höfler, J; Dobesberger, J; Kuchukhidze, G; Kreidenhuber, R; Florea, C; Thomschewski, A; Novak, HF; Pilz, G; Leitinger, M; Trinka, E;
Epilepsia. 2018; 59 Suppl 2: 234-242.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Panitumumab-Associated Encephalopathy after Accidental Intra-Arterial Application through Dislocated Central Venous Access Device
Sellner, J; Pilz, G; Gschwandtner, G; Rosler, C; Schlick, K; Greil, R; Pikija, S
ANN NEUROL. 2018; 84: S45-S45.
Abstracts (Journal)
2017
Journal Articles
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Harrer, A; Pilz, G; Oppermann, K; Sageder, M; Afazel, S; Haschke-Becher, E; Rispens, T; de Vries, A; McCoy, M; Stevanovic, V; Hitzl, W; Trinka, E; Kraus, J; Sellner, J; Wipfler, P;
Clin Immunol. 2017; 176: 87-93.
Full papers/articles (Journal)
Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome.
Pilz, G; Wipfler, P; Schwarte, O; Golaszewski, S; McCoy, M; Haschke-Becher, E; Hartung, HP; Kraus, J;
J Neurol. 2017; 264(4): 799-801.
Letters
Conference papers, proceedings, abstracts
BRIVARACETAM IN ESTABLISHED STATUS EPILEPTICUS: THE SALZBURG EXPERIENCE
Kalss, G; Rohracher, A; Leitinger, M; Pilz, G; Novak, HF; Neuray, C; Kreidenhuber, R; Hofler, J; Kuchukhidze, G; Trinka, E
EPILEPSIA. 2017; 58: S197-S197.
Abstracts (Journal)
2016
Journal Articles
(S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study.
Höfler, J; Rohracher, A; Kalss, G; Zimmermann, G; Dobesberger, J; Pilz, G; Leitinger, M; Kuchukhidze, G; Butz, K; Taylor, A; Novak, H; Trinka, E;
CNS Drugs. 2016; 30(9):869-876
Full papers/articles (Journal)
Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study.
Karamyan, A; Dünser, MW; Wiebe, DJ; Pilz, G; Wipfler, P; Chroust, V; Novak, HF; Hauer, L; Trinka, E; Sellner, J;
PLoS One. 2016; 11(5):e0155795
Full papers/articles (Journal)
Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device.
Pikija, S; Pilz, G; Gschwandtner, G; Rösler, C; Schlick, K; Greil, R; Sellner, J;
Front Neurol. 2016; 7:196
Case Reports
Conference papers, proceedings, abstracts
Evidence of gender differences for initiation of therapy escalation in multiple sclerosis
Karamyan, A; Oppermann, K; Bacher, C; Otto, F; Pilz, G; Wipfler, P; Chroust, V; Sellner, J
MULT SCLER J. 2016; 22: 723-723.
Abstracts (Journal)
Prevalence and predictors of sexual dysfunction in multiple sclerosis: a cross-sectional study
Otto, F; Bacher, C; Chroust, V; Karamyan, A; Oppermann, K; Reisp, M; Pilz, G; Wipfler, P; Sellner, J
MULT SCLER J. 2016; 22: 727-727.
Abstracts (Journal)
2015
Journal Articles
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer, A; Pilz, G; Wipfler, P; Oppermann, K; Sellner, J; Hitzl, W; Haschke-Becher, E; Afazel, S; Rispens, T; van der Kleij, D; Trinka, E; Kraus, J;
Clin Exp Immunol. 2015; 180(3):383-392
Full papers/articles (Journal)
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Harrer, A; Wipfler, P; Pilz, G; Oppermann, K; Haschke-Becher, E; Afazel, S; Kraus, J; Trinka, E; Sellner, J;
Int J Mol Sci. 2015; 16(9): 21832-21845.
Full papers/articles (Journal)
Predicting outcome of status epilepticus.
Leitinger, M; Kalss, G; Rohracher, A; Pilz, G; Novak, H; Hofler, J; Deak, I; Kuchukhidze, G; Dobesberger, J; Wakonig, A; Trinka, E
Epilepsy Behav. 2015; 49:126-130
Full papers/articles (Journal)
Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukencephalopathy with an excellent outcome
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Rispens, T; van der Kleij, D; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clinical and Experimental Neuroimmunology. 2015;
Case Reports
Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
Rohracher, A; Hofler, J; Kalss, G; Leitinger, M; Kuchukhidze, G; Deak, I; Dobesberger, J; Novak, H; Pilz, G; Zerbs, A; Trinka, E
EPILEPSY BEHAV. 2015; 49: 354-358.
Full papers/articles (Journal)
2014
Journal Articles
A routine-qualified flow cytometric method for the identification of multiple sclerosis patients with reduced therapy efficiency under natalizumab
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Sellner, J; Deisenhammer, F; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2014; 38(1): 17-23.
Full papers/articles (Journal)
Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Afazel, S; Haschke-Becher, E; Sellner, J; Trinka, E; Kraus, J;
Acta Neurol Scand. 2014; 129(3):e12-e15
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Natalizumab and fingolimod differentially impact the alpha-4/beta-1 and alpha-L/beta-2 expression-related subset diversity of T-cells
Harrer, A; Oppermann, K; Wanek, J; Pilz, G; Wipfler, P; Sellner, J; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2014; 20: 333-333.
Abstracts (Journal)
2013
Journal Articles
Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy.
Harrer, A; Tumani, H; Niendorf, S; Lauda, F; Geis, C; Weishaupt, A; Kleinschnitz, C; Rauer, S; Kuhle, J; Stangel, M; Weber, F; Uhr, M; Linnebank, M; Wildemann, B; Jarius, S; Guger, M; Ayzenberg, I; Chan, A; Zettl, U; Wiendl, H; Pilz, G; Hitzl, W; Weber, JR; Kraus, J;
Mult Scler. 2013; 19(9):1209-1212
Full papers/articles (Journal)
Tumefactive MS lesions under fingolimod: a case report and literature review.
Pilz, G; Harrer, A; Wipfler, P; Oppermann, K; Sellner, J; Fazekas, F; Trinka, E; Kraus, J;
Neurology. 2013; 81(19): 1654-1658.
Full papers/articles (Journal)
Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner, J; Koczi, W; Harrer, A; Oppermann, K; Obregon-Castrillo, E; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Clin Exp Immunol. 2013; 173(3):381-389
Full papers/articles (Journal)
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis.
Wipfler, P; Heikkinen, A; Harrer, A; Pilz, G; Kunz, A; Golaszewski, SM; Reuss, R; Oschmann, P; Kraus, J;
J Neurol. 2013; 260(1):221-227
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
KETAMINE IN REFRACTORY STATUS EPILEPTICUS - A RETROSPECTIVE STUDY ON 16 PATIENTS
Hofler, J; Zerbs, A; Dobesberger, J; Pilz, G; Leitinger, M; Novak, H; Trinka, E
EPILEPSIA. 2013; 54: 114-114.
Abstracts (Journal)
Flow-cytometry and the detection of natalizumab-neutralizing antibodies in multiple sclerosis
Oppermann, K; Harrer, A; Pilz, G; Wipfler, P; Holl, B; Deisenhammer, F; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J
MULT SCLER J. 2013; 19(11): 500-501.
Abstracts (Journal)
2012
Journal Articles
Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy.
Broussalis, E; Hutterer, M; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Haschke-Becher, E; Golaszewski, S; Schönauer, U; Weis, S; Killer-Oberpfalzer, M; Mc Coy, M; Trinka, E; Kraus, J;
Acta Neurol Scand. 2012; 126(3):e11-e16
Case Reports
Flow cytometry and drug monitoring of natalizumab saturation of immune cells in multiple sclerosis
Harrer, A; Oppermann, K; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, L; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 377-382.
Full papers/articles (Journal)
Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer, A; Pilz, G; Einhaeupl, M; Oppermann, K; Hitzl, W; Wipfler, P; Sellner, J; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
PLoS One. 2012; 7(2):e31784
Full papers/articles (Journal)
Overview of laboratory methods to monitor innovative treatment regimens in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Holl, B; Oppermann, K; Golaszewski, SM; Harrer, A
LABORATORIUMSMEDIZIN. 2012; 36(6): 389-396.
Reviews
Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz, G; Harrer, A; Oppermann, K; Wipfler, P; Golaszewski, S; Afazel, S; Haschke-Becher, E; Trinka, E; Kraus, J;
Mult Scler. 2012; 18(4):506-509
Full papers/articles (Journal)
Future relevance of CSF biomarkers in modern MS treatment
Pilz, G; Wipfler, P; Harrer, A; Holl, B; Oppermann, K; Golaszewski, SM; Trinka, E; Kraus, J
LABORATORIUMSMEDIZIN. 2012; 36(6): 383-388.
Full papers/articles (Journal)
2011
Journal Articles
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer, A; Wipfler, P; Einhaeupl, M; Pilz, G; Oppermann, K; Hitzl, W; Afazel, S; Haschke-Becher, E; Strasser, P; Trinka, E; Kraus, J;
J Neuroimmunol. 2011; 234(1-2):148-154
Full papers/articles (Journal)
Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.
Wipfler, P; Harrer, A; Pilz, G; Oppermann, K; Trinka, E; Kraus, J;
Drug Discov Today. 2011; 16(1-2):8-21
Reviews
Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J;
Mult Scler. 2011; 17(1):16-23
Full papers/articles (Journal)
Acute pulmonary edema caused by a multiple sclerosis relapse.
Wipfler, P; Pilz, G; Broussalis, E; Golaszewski, SM; Kunz, A; Trinka, E; Kraus, J;
J Neurol. 2011; 258(6): 1176-1179.
Letters
2010
Journal Articles
Relationship between thrombin generation and carotid intima-media thickness.
Bernhard, H; Wipfler, P; Leschnik, B; Novak, M; Kraus, J; Pilz, G; Ladurner, G; Muntean, W;
HAMOSTASEOLOGIE. 2010; 30 Suppl 1: S168-S171.
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Continuous Down-Regulation of VLA-4 and Accumulation of Natalizumab at the VLA-4 Receptor: Potential Molecular Basis of Enhanced Treatment Efficacy and Occurrence of Opportunistic Infections
Kraus, J; Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Afazel, S; Haschke-Becher, E; Kunz, AB; Golaszewski, SM; Staffen, W; Ladurner, G
NEUROLOGY. 2010; 74(9): A416-A416.
Abstracts (Journal)
Short- and long-term decrease of soluble adhesion molecules (sICAM-1,-2,-3 and sVCAM-1) during natalizumab treatment
Oppermann, K; Pilz, G; Wipfler, P; Harrer, A; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S220-S220.
Abstracts (Journal)
Expression levels of cell surface bound interferon-receptor remain stable during short- and long-term interferon beta-1b treatment
Oppermann, K; Wipfler, P; Pilz, G; Harrer, A; Duerr, EM; Koczi, W; Sulzer, C; Afazel, S; Haschke-Becher, E; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S219-S219.
Abstracts (Journal)
Relationship between markers of endothelial damage and intima-media thickness in asymptomatic subjects
Wipfler, P; Bernhard, H; Leschnik, B; Pilz, G; Kraus, J; Muntean, W
J NEUROL. 2010; 257: S86-S86.
Abstracts (Journal)
Accumulation of natalizumab at the VLA-4 receptor as a potential molecular basis of enhanced treatment efficacy and occurrence of opportunistic infections
Wipfler, P; Oppermann, K; Pilz, G; Harrer, A; Haschke-Becher, E; Kunz, A; Golaszewski, S; Ladurner, G; Kraus, J
J NEUROL. 2010; 257: S8-S8.
Abstracts (Journal)
2009
Journal Articles
Goat Cheese and Spondylodiscitis
Pilz, G; Hold, R; Wipfler, P; Iglseder, B; Hell, M; Golaszewski, S; Ladurner, G; Kraus, J
AKTUEL NEUROL. 2009; 36(8): 418-420.
Case Reports
Conference papers, proceedings, abstracts
Endogenous thrombin potential is associated with carotid intima-media thickness in subjects younger than 45 years
Wipfler, P; Bernhard, H; Pilz, G; Kraus, J; Afazel, S; Ladurner, G; Leschnik, B; Novak, M; Muntean, W
J NEUROL. 2009; 256: S51-S51.
Abstracts (Journal)
2008
Journal Articles
Modern multiple sclerosis treatment - what is approved, what is on the horizon.
Pilz, G; Wipfler, P; Ladurner, G; Kraus, J;
Drug Discov Today. 2008; 13(23-24):1013-1025
Reviews
Klebsiella meningoencephalitis presenting like embolic ischemic stroke.
Wipfler, P; Pilz, G; Lesicky, O; Golaszewski, SM; Ladurner, G; Kraus, J;
J NEUROL. 2008; 255(12): 1983-1984.
Letters
Conference papers, proceedings, abstracts
Changes in adhesion molecule expression induced by natalizumab treatment in multiple sclerosis
Kraus, J; Pilz, G; Wipfler, P; Afazel, S; Haschke-Becher, E; Huemer, M; Jakab, M; Ritter, M; Ladurner, G
MULT SCLER. 2008; 14: S133-S133.
Abstracts (Journal)
2007
Journal Articles
Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells.
Falkensammer, B; Pilz, G; Bektić, J; Imwidthaya, P; Jöhrer, K; Speth, C; Lass-Flörl, C; Dierich, MP; Würzner, R;
Mycoses. 2007; 50(3):172-177
Full papers/articles (Journal)
Conference papers, proceedings, abstracts
Perfusion abnormalities in cerebral magnetic resonance imaging in two patients with prolonged mirgrainous aura
Kraus, J; Golaszewski, S; Luthringshausen, G; Hold, R; Pilz, G; Ladurner, G
J NEUROL. 2007; 254: 142-142.
Abstracts (Journal)